ASCO GU 2023

Robust DFS benefit, but lack of OS data leaves open questions

New updates on immunocheckpoint inhibitors and ADCs - which therapy for which patient?

Bladder preservation strategies - promising data but no change in SoC yet?!

No change in SoC, but new genomic predictors for EV outcome

Final OS data show no significant benefit for chemo plus ICI

Benefit of neoadjuvant pembro for CE and CI patients

Atezo monotherapy for mUC

Pembro for HR NMIBC

Re-shaping bladder cancer treatment

Final overall survival

Update / German Real World Data M1 BC

No final OS difference - but subgroups may benefit from Atezolizumab

IMvigor130: final OS

Urothelial cancer highlights from ASCO GU23

PD-1 as combo in 1st line

New data for pembro in HR NIMBC

3 yrs outcome of Nivo for adjuvant therapy

Impressive DFS with adjuvant Nivo in biomarker-positive patients

Urothelial cancer - hidden gems of the poster session

Checkpoint inhibition in adjuvant therapy

Pembrolizumab in HR NIMBC

The bladder cancer highlights of ASCO GU

Exciting survival data for adjuvant NIVO

NMIBC highlights from ASCO GU23

The bladder cancer highlights of ASCO GU

Refinando el tratamiento del cancere vejiga

BCG yanıtsız yüksek riskli KİOMK tedavisinde Pembrolizumab

Επισημάνσεις για τον καρκίνο του ουροθηλίου από την ASCO GU23

PARPi are effective in PCa - which subgroups benefits most?

Los aspectos más destacados del ASCO GU 2023 en cáncer de vejiga

Benefits and risks of precision medicine with PARPi

Triplet combination - all-comer therapy or high risk high volume only? How do we identify the patients who benefit?

BRCA mutations in mCRPC - the importance of biomarkers in PCa! Why we need better testing and better understanding of therapy combinations!

New ways to target androgen receptor signaling

Doublet or all-in: the solution for all patients?

ARASENS - post-hoc subgroup analysis

Formula 509: Racing to a better straegy for radiotherapy

Controversy in ADT roundtable

ARASENS: triple independent of volume and risk

Surgery vs. Radiation for N1 PCa: who wins?

mHSPC - new standard and more insights

Benefit in all groups

Normal baseline testosterone level is a strong predictor of post-ADT recovery

PARP and testing

Monotherapy is not any longer standard of care

Intensification of salvage therapy in high risk settings

MMAI - a superior prognostic marker for high risk patients

PARPi study with different design

Rucaparib: treatment option for biomarker-selected patients

PARPi combo approval for all-comers - balancing benefit of treamtent vs. side effects is crucial

TALA in 1st line for all patients with mCRPC

Propel - final OS

PARPi combination in mCRPC

Rucaparib - the new player?

PARPi combo: all-comer treatment for mCRPC

Rucaparib - ready for clinical practice in BRCAmut patients

Tiebreaker for previous trials

TALA ENZO with improved PFS in mCRPC

PARPi are effective in PCa - which subgroup benefits most?

Encouraging results for Talazoparib

PARPi & ARPi with wonderful data

Ny PARP hämmar studie med anna design

Lokalize prostat kanserinde cerrahi ile SBRT karşılaştıran faz-3 randomize kontrollü çalışma

TALA ENZA kombinasyonu ile mKDPK olan hastalarda daha iyi progresyonsuz sağkalım

edavi öncesi normal testosteron seviyesi ADT sonrası testosteron geri dönüşü için güçlü bir prediktördür

Nya vägar att blockera androgenreceptor signalering

RP sonrası kurtarma RT ile GnRH Analog ABİ APA kombinasyonu, kurtarma RT ve GnRH analog tedavisinden daha iyi PFS sağlar mı?

MMAI- Yüksek riskli prostat kanserinde üstün bir prognostik belirteç

PARPi & ARPi με υπέροχα δεδομένα

miR371'in orşiektomi sonrası tedavi seçimini yönlendirmekteki yüksek doğruluğu

Novel updates on cabozantinib in advance RCC

Updated data of CheckMate 9ER - impact on real-world therapy

Theranostics in RCC - usefull tools for ccRCC?!

First prospective data on 2nd line therapy after IO combination in mRCC

Hypothesis-generating differences in risks groups

New therapy choices for renal cell cancer patients

Longer FU confirms significant benefit of Nivo-Cabo, Cabo effective post IO first line

Outcomes of patients with brain metastases treated with first-line therapies

Reassuring update of CM9ER with longer follow up

Zircon-PET in RCC

Refining prediction of stage I seminoma

microbiom & CPI perspectives

High accuracy of miR371 to guide treatment selection after orchiectomy

Mejorando la estimacion pronostica en Seminoma Estadio I